BIBF-1202 _VEGFR 抑制劑 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEBIBF 1202Cat. No.: HY-15992CAS No.: 894783-71-2分式: CHNO分量: 525.6作靶點(diǎn): VEGFR作通路: Protein Tyrosine Kinase/RTK儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 45 mg/mL (85.62 mM)* means soluble,

2、 but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 1.9026 mL 9.5129 mL 19.0259 mL5 mM 0.3805 mL 1.9026 mL 3.8052 mL10 mM 0.1903 mL 0.9513 mL 1.9026 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 BIBF 1202是BIBF 1120的羧酸鹽代謝物，抑制 VEGFR2 激酶的 IC50 值為62 nM。IC50

3、& Target IC50: 62 nM (VEGFR2) 1體外研究 The major metabolic pathway for BIBF 1120 is methyl ester cleavage to BIBF 1202. Subsequently, the freecarboxyl group of BIBF 1202 is glucuronidated to 1-O-acylglucuronide 2.1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEREFERENCES1. Hilberg F, et al. BIBF 1120:

4、 triple angiokinase inhibitor with sustained receptor blockade and good antitumorefficacy. Cancer Res. 2008Jun 15;68(12):4774-82.2. Stopfer P, et al. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica. 2011Apr;41(4):297-311.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792;Fax: 0